The Discovery That Will Change The Face Of Medicine
Code Pharma develops products working in a dual manner;
Antiviral effect against RNA viruses
Destruction of cells infected with HIV and Cancer cells.
- Antiviral effect against RNA viruses such as SARS-CoV-2 and Influenza virus.
- Promoting specifically the death of the HIV infected and Cancer cells
- Non-toxic with minimal side effects
- Code Pharma present this new experimental drugs, named Codivir
Codivir contains peptides derived from HIV virus that promote infected cells into self-induced death (apoptosis), and Lentivirus manipulation in the case of cancer therapy.
This process can treat both illnesses by killing the infected cells without harm to normal cells
Codivir is a peptide leading to antiviral effect against RNA viruses.
- Demonstrated the effectiveness of the peptides to eradicate HIV infected human cultured cells in Israel (Hebrew U.)
- Demonstrated the activity of the peptide on HIV infected mice cultured cells in N.Y. (Volsky)
- Demonstrated the activity of the peptides when using lentiviral particles as the vehicle to introduce the “killing genes”.
In Israel (Smart Assay Labs- Rehovot)
- Demonstrated the effectiveness of the peptides on blood drown from HIV patients.
In Israel (Kaplan Medical Center, Rehovot)
- Demonstrated the activity of the peptides together with lentiviral particles in lung cancer cells and pancreatic cancer cell. (Tel Aviv Sourasky Medical Center and Kaplan medical center, Rehovot).
- Demonstrated antiviral effect for RNA viruses such as SARS-CoV-2 and Influenza virus (Virology Research Services in London, UK)
- First in Human clinical trial in HIV patients (Entebbe, Uganda)
- Compassionate treatments in patients of other indications; Cancer, COVID-19 patients (Israel, Congo).